PMID- 7931484
OWN - NLM
STAT- MEDLINE
DCOM- 19941104
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 12
IP  - 10
DP  - 1994 Oct
TI  - Treatment of children with clear-cell sarcoma of the kidney: a report from the 
      National Wilms' Tumor Study Group.
PG  - 2132-7
AB  - PURPOSE: To evaluate the effect of the sequential addition of doxorubicin (DOX) 
      and cyclophosphamide (CTX) to the combination of vincristine (VCR) and 
      dactinomycin (AMD) on the relapse-free survival of children with clear-cell 
      sarcoma of the kidney (CCSK). PATIENTS AND METHODS: We determined the 6-year 
      relapse-free survival rate for patients with CCSK treated on National Wilms' 
      Tumor Study (NWTS)-1, NWTS-2, or NWTS-3 with the combination of VCR and AMD, with 
      or without DOX, and for patients treated on NWTS-3 with the combination of VCR, 
      AMD, and DOX with (regimen J) or without (regimen DD-RT) CTX. RESULTS: The 6-year 
      relapse-free survival rate for the eight children with CCSK treated with VCR, 
      AMD, and radiation therapy was 25.0%, compared with 63.5% for the 58 children 
      treated with VCR, AMD, DOX, and radiation therapy (P = .09). The 6-year 
      relapse-free survival rate for children with CCSK treated on regimen DD-RT was 
      64.6%, compared with 58.2% for those treated on regimen J (P = .79). CONCLUSION: 
      We conclude that the addition of DOX to the combination of VCR plus AMD appeared 
      to improve the 6-year relapse-free survival rate of children with CCSK. The 
      addition of CTX in the dose and schedule used in NWTS-3 did not improve the 
      6-year relapse-free survival rate of children with CCSK. Because 30% of relapses 
      occurred more than 2 years after diagnosis, prolonged follow-up evaluation of 
      patients with CCSK is necessary.
FAU - Green, D M
AU  - Green DM
AD  - Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263.
FAU - Breslow, N E
AU  - Breslow NE
FAU - Beckwith, J B
AU  - Beckwith JB
FAU - Moksness, J
AU  - Moksness J
FAU - Finklestein, J Z
AU  - Finklestein JZ
FAU - D'Angio, G J
AU  - D'Angio GJ
LA  - eng
GR  - CA-4256/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Dactinomycin/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/radiotherapy
MH  - Male
MH  - Neoplasms, Germ Cell and Embryonal/*drug therapy/radiotherapy
MH  - Proportional Hazards Models
MH  - United States
MH  - Vincristine/administration & dosage
MH  - Wilms Tumor
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1200/JCO.1994.12.10.2132 [doi]
PST - ppublish
SO  - J Clin Oncol. 1994 Oct;12(10):2132-7. doi: 10.1200/JCO.1994.12.10.2132.